肝X受体
ABCA1
细胞生长
生物
兴奋剂
癌症研究
胆固醇
核受体
胆固醇逆向转运
细胞凋亡
细胞生物学
受体
内分泌学
脂蛋白
生物化学
运输机
基因
转录因子
作者
KOREHITO KASHIWAGI,Hanako Sato-Yazawa,Jun Ishii,Kakeru Kohno,ISAAKI TATSUTA,Tadasuke Miyazawa,Megumi Takagi,Hideki Chiba,Takuya Yazawa
出处
期刊:Anticancer Research
[Anticancer Research USA Inc.]
日期:2022-05-31
卷期号:42 (6): 2923-2930
被引量:1
标识
DOI:10.21873/anticanres.15774
摘要
Liver X receptors (LXRs) are nuclear receptors with various functions, including the regulation of cholesterol metabolism, glucose homeostasis, and inflammation. We previously reported that LXR activation inhibits the growth of oral cancer cells by inducing cellular cholesterol efflux and that LXRβ is expressed mainly in small-cell lung cancer (SCLC) tissues. SCLC is one of the most aggressive cancers, and identifying an effective therapeutic target molecule is desirable. Therefore, we investigated whether LXRβ could be an effective target molecule for SCLC treatment through in vitro experiments.We evaluated the influence of treatment with the LXR agonist T0901317 on cell proliferation and apoptosis in SCLC cell lines using cell viability, BrdU-ELISA, FACS, and western blot analyses. Moreover, the mechanism by which T0901317 inhibits SCLC cell proliferation was elucidated using qRT-PCR, western blot, a cholesterol quantification assay, and a genome editing technique.We showed that cultivated SCLC cells expressed LXRβ and that an LXR agonist inhibited the proliferation of SCLC cells without toxicity to normal cells. Furthermore, the antitumoral effect of an LXR agonist on SCLC cells was attributed to the induction of ABCA1 by LXRβ activation, resulting in an increase in cellular cholesterol efflux via ABCA1.The activation of LXRβ up-regulates ABCA1 expression, causing cholesterol depletion in cancer cells. This mechanism could be a novel target strategy for SCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI